---
document_datetime: 2025-12-09 23:24:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/efficib.html
document_name: efficib.html
version: success
processing_time: 0.1390343
conversion_datetime: 2025-12-24 14:51:06.297669
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Efficib

[RSS](/en/individual-human-medicine.xml/66617)

##### Authorised

This medicine is authorised for use in the European Union

sitagliptin / metformin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Efficib](#news-on)
- [More information on Efficib](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Efficib. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Efficib.

Expand section

Collapse section

## What is Efficib?

Efficib is a medicine that contains two active substances, sitagliptin and metformin hydrochloride. It is available as tablets (50 mg sitagliptin / 850 mg metformin hydrochloride; and 50 mg sitagliptin / 1,000 mg metformin hydrochloride).

## What is Efficib used for?

Efficib is used in patients with type-2 diabetes to improve the control of blood glucose (sugar) levels.

It is used in addition to diet and exercise in the following ways:

- in patients who are not satisfactorily controlled on metformin (an antidiabetes medicine) used on its own;
- in patients who are already taking a combination of sitagliptin and metformin as separate tablets;
- in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin (other types of antidiabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.

The medicine can only be obtained with a prescription.

## How is Efficib used?

Efficib is taken twice a day. The strength of tablet to use depends on the dose of the other antidiabetes medicines that the patient was taking before. If Efficib is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).

The maximum dose of sitagliptin is 100 mg a day. Efficib should be taken with food to avoid any stomach problems caused by metformin.

## How does Efficib work?

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substances in Efficib, sitagliptin and metformin hydrochloride, each have a different mode of action.

Sitagliptin is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. It works by blocking the breakdown of 'incretin' hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing the levels of incretin hormones in the blood, sitagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Sitagliptin does not work when the blood glucose is low. Sitagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Sitagliptin has been authorised in the European Union (EU) as Januvia and Xelevia since 2007, and as Tesavel since 2008. Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.

Metformin has been available in the EU since the 1950s. As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type-2 diabetes.

## How has Efficib been studied?

Sitagliptin on its own as Januvia / Xelevia / Tesavel can be used with metformin, and with both metformin and a sulphonylurea, in type-2-diabetes patients. The company presented the results of three studies of Januvia / Xelevia to support the use of Efficib in patients who were not satisfactorily controlled on their existing metformin treatment.

Two of the studies looked at sitagliptin as an add-on to metformin: the first compared it with placebo (a dummy treatment) in 701 patients, and the second compared it with glipizide (a sulphonylurea) in 1,172 patients. The third study compared sitagliptin with placebo, when used as an add-on to glimepiride (another sulphonylurea), with or without metformin, in 441 patients.

The results of three further studies were used to support the use of Efficib. The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Efficib with that of metformin or sitagliptin alone. The second included 278 patients who were not satisfactorily controlled on the combination of metformin and rosiglitazone (a PPAR-gamma agonist) and compared the effects of adding sitagliptin or placebo. The third included 641 patients who were not satisfactorily controlled on a stable dose of insulin, three quarters of whom were also taking metformin. This study also compared the effects of adding sitagliptin or placebo.

In all of the studies, the main measure of effectiveness was the change in the levels of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.

The company also carried out additional studies to show that the active substances in Efficib are absorbed by the body in the same way as the two medicines given separately.

## What benefit has Efficib shown during the studies?

Efficib was more effective than metformin alone. Adding 100 mg sitagliptin to metformin reduced HbA1c levels by 0.67% (from around 8.0%) after 24 weeks, compared with a fall of 0.02% in the patients adding placebo. The effectiveness of adding sitagliptin to metformin was similar to that of adding glipizide. In the study in which sitagliptin was added to glimepiride and metformin, the levels of HbA1c were reduced by 0.59% after 24 weeks, compared with an increase of 0.30% in the patients adding placebo.

In the first of the three further studies, Efficib was more effective than metformin or sitagliptin alone.

In the second, HbA1c levels were reduced by 1.03% after 18 weeks in patients adding sitagliptin to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo. Finally, they were reduced by 0.59% after 24 weeks in patients adding sitagliptin to insulin, compared with a fall of 0.03% in those adding placebo. There was no difference in this effect between the patients also taking metformin and those not taking it.

## What is the risk associated with Efficib?

The most common side effect with Efficib (seen in between 1 and 10 patients in 100) is nausea (feeling sick). For the full list of all side effects reported with Efficib, see the package leaflet.

Efficib must not be used in people who are hypersensitive (allergic) to sitagliptin, metformin or any of the other ingredients. It must not be used in patients who have diabetic ketoacidosis or pre-coma (dangerous conditions that can occur in diabetes), problems with the kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack. It must also not be used in patients who consume excessive amounts of alcohol or are alcoholic, or in women who are breast-feeding. For the full list of restrictions, see the package leaflet.

## Why has Efficib been approved?

The CHMP decided that Efficib's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Efficib

The European Commission granted a marketing authorisation valid throughout the EU for Efficib on 16 July 2008.

For more information about treatment with Efficib, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Efficib : EPAR - Summary for the public

English (EN) (81.49 KB - PDF)

**First published:** 08/12/2009

**Last updated:** 05/07/2013

[View](/en/documents/overview/efficib-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-820)

български (BG) (136.62 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/bg/documents/overview/efficib-epar-summary-public_bg.pdf)

español (ES) (106.12 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/es/documents/overview/efficib-epar-summary-public_es.pdf)

čeština (CS) (133.38 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/cs/documents/overview/efficib-epar-summary-public_cs.pdf)

dansk (DA) (104.46 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/da/documents/overview/efficib-epar-summary-public_da.pdf)

Deutsch (DE) (84.97 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/de/documents/overview/efficib-epar-summary-public_de.pdf)

eesti keel (ET) (113.03 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/et/documents/overview/efficib-epar-summary-public_et.pdf)

ελληνικά (EL) (150.71 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/el/documents/overview/efficib-epar-summary-public_el.pdf)

français (FR) (106.99 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/fr/documents/overview/efficib-epar-summary-public_fr.pdf)

italiano (IT) (105.31 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/it/documents/overview/efficib-epar-summary-public_it.pdf)

latviešu valoda (LV) (106.66 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/lv/documents/overview/efficib-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (130.08 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/lt/documents/overview/efficib-epar-summary-public_lt.pdf)

magyar (HU) (103.93 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/hu/documents/overview/efficib-epar-summary-public_hu.pdf)

Malti (MT) (110.98 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/mt/documents/overview/efficib-epar-summary-public_mt.pdf)

Nederlands (NL) (83.68 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/nl/documents/overview/efficib-epar-summary-public_nl.pdf)

polski (PL) (133.78 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/pl/documents/overview/efficib-epar-summary-public_pl.pdf)

português (PT) (105.35 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/pt/documents/overview/efficib-epar-summary-public_pt.pdf)

română (RO) (129.44 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/ro/documents/overview/efficib-epar-summary-public_ro.pdf)

slovenčina (SK) (131.27 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/sk/documents/overview/efficib-epar-summary-public_sk.pdf)

slovenščina (SL) (122.57 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/sl/documents/overview/efficib-epar-summary-public_sl.pdf)

Suomi (FI) (103.85 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/fi/documents/overview/efficib-epar-summary-public_fi.pdf)

svenska (SV) (104.04 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

05/07/2013

[View](/sv/documents/overview/efficib-epar-summary-public_sv.pdf)

Efficib : EPAR - Risk-management-plan summary

English (EN) (74.35 KB - PDF)

**First published:** 31/05/2022

[View](/en/documents/rmp-summary/efficib-epar-risk-management-plan-summary_en.pdf)

## Product information

Efficib : EPAR - Product Information

English (EN) (428.82 KB - PDF)

**First published:** 08/12/2009

**Last updated:** 01/12/2025

[View](/en/documents/product-information/efficib-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-468)

български (BG) (393.36 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/bg/documents/product-information/efficib-epar-product-information_bg.pdf)

español (ES) (469.13 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/es/documents/product-information/efficib-epar-product-information_es.pdf)

čeština (CS) (438.23 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/cs/documents/product-information/efficib-epar-product-information_cs.pdf)

dansk (DA) (452.04 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/da/documents/product-information/efficib-epar-product-information_da.pdf)

Deutsch (DE) (486.89 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/de/documents/product-information/efficib-epar-product-information_de.pdf)

eesti keel (ET) (452.74 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/et/documents/product-information/efficib-epar-product-information_et.pdf)

ελληνικά (EL) (408.75 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/el/documents/product-information/efficib-epar-product-information_el.pdf)

français (FR) (484.37 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/fr/documents/product-information/efficib-epar-product-information_fr.pdf)

hrvatski (HR) (445.36 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/hr/documents/product-information/efficib-epar-product-information_hr.pdf)

íslenska (IS) (426.25 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/is/documents/product-information/efficib-epar-product-information_is.pdf)

italiano (IT) (486.9 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/it/documents/product-information/efficib-epar-product-information_it.pdf)

latviešu valoda (LV) (403.48 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/lv/documents/product-information/efficib-epar-product-information_lv.pdf)

lietuvių kalba (LT) (429.7 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/lt/documents/product-information/efficib-epar-product-information_lt.pdf)

magyar (HU) (495.07 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/hu/documents/product-information/efficib-epar-product-information_hu.pdf)

Malti (MT) (459.54 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/mt/documents/product-information/efficib-epar-product-information_mt.pdf)

Nederlands (NL) (448.36 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/nl/documents/product-information/efficib-epar-product-information_nl.pdf)

norsk (NO) (435.79 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/no/documents/product-information/efficib-epar-product-information_no.pdf)

polski (PL) (462.61 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/pl/documents/product-information/efficib-epar-product-information_pl.pdf)

português (PT) (472.14 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/pt/documents/product-information/efficib-epar-product-information_pt.pdf)

română (RO) (445.07 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/ro/documents/product-information/efficib-epar-product-information_ro.pdf)

slovenčina (SK) (466.82 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/sk/documents/product-information/efficib-epar-product-information_sk.pdf)

slovenščina (SL) (445.6 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/sl/documents/product-information/efficib-epar-product-information_sl.pdf)

Suomi (FI) (466.7 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/fi/documents/product-information/efficib-epar-product-information_fi.pdf)

svenska (SV) (447 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/sv/documents/product-information/efficib-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000314786 27/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Efficib : EPAR - All Authorised presentations

English (EN) (20.94 KB - PDF)

**First published:** 14/05/2009

**Last updated:** 27/03/2014

[View](/en/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-765)

български (BG) (38.84 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/bg/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.81 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/es/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.03 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/cs/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.58 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/da/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.34 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/de/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.18 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/et/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (60.84 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/el/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_el.pdf)

français (FR) (16.19 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/fr/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.33 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/hr/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (19.66 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/is/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.34 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/it/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.03 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/lv/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.76 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/lt/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34.42 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/hu/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (36.22 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/mt/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.36 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/nl/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.27 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/no/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_no.pdf)

polski (PL) (32.57 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/pl/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.37 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/pt/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.51 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/ro/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.7 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/sk/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.17 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/sl/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.83 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/fi/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.32 KB - PDF)

**First published:**

14/05/2009

**Last updated:**

27/03/2014

[View](/sv/documents/all-authorised-presentations/efficib-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Efficib Active substance

- sitagliptin
- metformin hydrochloride

International non-proprietary name (INN) or common name

- sitagliptin
- metformin

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BD07

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

For patients with type-2 diabetes mellitus:

- Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
- Efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
- Efficib is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.
- Efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

## Authorisation details

EMA product number EMEA/H/C/000896 Marketing authorisation holder

Merck Sharp and Dohme B.V

Waarderweg 39

Opinion adopted 24/04/2008 Marketing authorisation issued 15/07/2008 Revision 37

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Efficib : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.38 KB - PDF)

**First published:** 28/05/2025

**Last updated:** 01/12/2025

[View](/en/documents/procedural-steps-after/efficib-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Efficib : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (285 KB - PDF)

**First published:** 08/12/2009

**Last updated:** 28/05/2025

[View](/en/documents/procedural-steps-after/efficib-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Efficib-H-C-896-WS-1898 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/603247/2020

English (EN) (1.16 MB - PDF)

**First published:** 17/12/2020

[View](/en/documents/variation-report/efficib-h-c-896-ws-1898-epar-assessment-report-variation_en.pdf)

Efficib-H-C-PSUSA-00002003-201708 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/423583/2018

English (EN) (66.01 KB - PDF)

**First published:** 02/07/2018

**Last updated:** 02/07/2018

[View](/en/documents/scientific-conclusion/efficib-h-c-psusa-00002003-201708-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Efficib : EPAR - Scientific Conclusion

English (EN) (133.88 KB - PDF)

**First published:** 22/12/2016

**Last updated:** 22/12/2016

[View](/en/documents/scientific-conclusion/efficib-epar-scientific-conclusion_en.pdf)

[Other languages (24)](#file-language-dropdown-226)

български (BG) (150.06 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/bg/documents/scientific-conclusion/efficib-epar-scientific-conclusion_bg.pdf)

español (ES) (148.06 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/es/documents/scientific-conclusion/efficib-epar-scientific-conclusion_es.pdf)

čeština (CS) (135.64 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/cs/documents/scientific-conclusion/efficib-epar-scientific-conclusion_cs.pdf)

dansk (DA) (136.67 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/da/documents/scientific-conclusion/efficib-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (138.06 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/de/documents/scientific-conclusion/efficib-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (147.54 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/et/documents/scientific-conclusion/efficib-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (150.73 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/el/documents/scientific-conclusion/efficib-epar-scientific-conclusion_el.pdf)

français (FR) (136.32 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/fr/documents/scientific-conclusion/efficib-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (148.82 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/hr/documents/scientific-conclusion/efficib-epar-scientific-conclusion_hr.pdf)

íslenska (IS) (27.8 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/is/documents/scientific-conclusion/efficib-epar-scientific-conclusion_is.pdf)

italiano (IT) (148.8 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/it/documents/scientific-conclusion/efficib-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (177.39 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/lv/documents/scientific-conclusion/efficib-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (135.43 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/lt/documents/scientific-conclusion/efficib-epar-scientific-conclusion_lt.pdf)

magyar (HU) (133.47 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/hu/documents/scientific-conclusion/efficib-epar-scientific-conclusion_hu.pdf)

Malti (MT) (84.67 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/mt/documents/scientific-conclusion/efficib-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (150.99 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/nl/documents/scientific-conclusion/efficib-epar-scientific-conclusion_nl.pdf)

norsk (NO) (133.99 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/no/documents/scientific-conclusion/efficib-epar-scientific-conclusion_no.pdf)

polski (PL) (137.51 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/pl/documents/scientific-conclusion/efficib-epar-scientific-conclusion_pl.pdf)

português (PT) (151.14 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/pt/documents/scientific-conclusion/efficib-epar-scientific-conclusion_pt.pdf)

română (RO) (147.61 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/ro/documents/scientific-conclusion/efficib-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (154.25 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/sk/documents/scientific-conclusion/efficib-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (128.2 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/sl/documents/scientific-conclusion/efficib-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (148.06 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/fi/documents/scientific-conclusion/efficib-epar-scientific-conclusion_fi.pdf)

svenska (SV) (133.2 KB - PDF)

**First published:**

22/12/2016

**Last updated:**

22/12/2016

[View](/sv/documents/scientific-conclusion/efficib-epar-scientific-conclusion_sv.pdf)

Efficib-H-C-896-A31-1432 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/CHMP/539626/2016

English (EN) (569.41 KB - PDF)

**First published:** 22/12/2016

**Last updated:** 22/12/2016

[View](/en/documents/variation-report/efficib-h-c-896-a31-1432-epar-assessment-report-article-31_en.pdf)

Efficib-H-C-896-II-0004 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/752888/2009

English (EN) (448.77 KB - PDF)

**First published:** 08/12/2009

**Last updated:** 08/12/2009

[View](/en/documents/variation-report/efficib-h-c-896-ii-0004-epar-assessment-report-variation_en.pdf)

CHMP post authorisation summary of positive opinion for Efficib of 24 September 2009

Adopted

Reference Number: EMEA/CHMP/544759/2009

English (EN) (33.39 KB - PDF)

**First published:** 24/09/2009

**Last updated:** 24/09/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-efficib-24-september-2009_en.pdf)

Efficib-H-C-896-II-0013 : EPAR - Assessment Report - Variation

Reference Number: EMEA/350880/2009

English (EN) (906.19 KB - PDF)

**First published:** 06/07/2009

**Last updated:** 06/07/2009

[View](/en/documents/variation-report/efficib-h-c-896-ii-0013-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Efficib of 23 April 2009

Adopted

Reference Number: EMEA/CHMP/240565/2009

English (EN) (33.35 KB - PDF)

**First published:** 23/04/2009

**Last updated:** 23/04/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-efficib-23-april-2009_en.pdf)

## Initial marketing authorisation documents

Efficib : EPAR - Public assessment report

English (EN) (648.29 KB - PDF)

**First published:** 06/08/2008

**Last updated:** 06/08/2008

[View](/en/documents/assessment-report/efficib-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Efficib

Reference Number: EMEA/CHMP/216662/2008-corr

English (EN) (34.95 KB - PDF)

**First published:** 29/04/2008

**Last updated:** 29/04/2008

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-efficib_en.pdf)

#### News on Efficib

[Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function](/en/news/use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function) 14/10/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Investigation into GLP-1-based diabetes therapies concluded](/en/news/investigation-glp-1-based-diabetes-therapies-concluded) 26/07/2013

[European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes](/en/news/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes) 26/03/2013

#### More information on Efficib

- [Sitagliptin phosphate monohydrate, metformin hydrochloride - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/sitagliptin-phosphate-monohydrate-metformin-hydrochloride-1)
- [Metformin and metformin-containing medicines - referral](/en/medicines/human/referrals/metformin-metformin-containing-medicines)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 01/12/2025

## Share this page

[Back to top](#main-content)